FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

V H J van der Velden

Research Profile

Disorders

Procedures

Chemicals & Drugs

Physiology

Genes & Molecular Sequences

Co-author Network

Publications

TOP 3
B Denys; C Homburg; Jan Philippé; R Pieters; C Ellen van der Schoot; AJ van der Sluijs-Gelling; V de Haas; J J M van Dongen; V H J van der Velden
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
M Bellido; Frank W G Leebeek; V H J van der Velden; P A W te Boekhorst
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?
Tomas Kalina; L Lhermitte; M Martin-Ayuso; Ester Mejstrikova; A Mendonça; Alberto Orfao; José J Pérez; Matthias Ritgen; L Sedek; T Szczepański; Jeroen te Marvelde; V H J van der Velden; J J M van Dongen; María-Belén Vidriales; Julia Almeida; Vahid Asnafi; Sebastian Böttcher; M Cullen; R de Tute; J Flores-Montero; Ondrej Hrusak
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of V H J van der Velden (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: B Denys; C Homburg; Jan Philippé; R Pieters; C Ellen van der Schoot; AJ van der Sluijs-Gelling; V de Haas; J J M van Dongen; V H J van der Velden
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Leukemia 2013;27(3):635-41.
2012: M Bellido; Frank W G Leebeek; V H J van der Velden; P A W te Boekhorst
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?
Annals of hematology 2012;91(12):1969-70.
2012: Tomas Kalina; L Lhermitte; M Martin-Ayuso; Ester Mejstrikova; A Mendonça; Alberto Orfao; José J Pérez; Matthias Ritgen; L Sedek; T Szczepański; Jeroen te Marvelde; V H J van der Velden; J J M van Dongen; María-Belén Vidriales; Julia Almeida; Vahid Asnafi; Sebastian Böttcher; M Cullen; R de Tute; J Flores-Montero; Ondrej Hrusak
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.
Leukemia 2012;26(9):1986-2010.
2012: E H A Dekking; E P Dixon; P Evans; J Flores-Montero; P Hoogeveen; Tomas Kalina; V Kanderová; Michael Kneba; A Koning; Paulo Lucio; A Mendonça; A L Noordijk; Alberto Orfao; L Sedek; E Sonneveld; T Szczepański; V H J van der Velden; J J M van Dongen; N Van Poecke; R Varro; P M Vermeulen; Hobert Wai; Julia Almeida; Nancy Boeckx; Sebastian Böttcher; M C Chillón; W Marieke Comans-Bitter; M Cullen; M T de Man
Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia.
Leukemia 2012;26(9):1976-85.
2012: Marjolein Blink; Rodrigo T Calado; Valerie de Haas; Henrik Hasle; Iris H I M Hollink; Jan-Henning Klusmann; Jules P P Meijerink; Rob Pieters; Dirk Reinhardt; Marry M van den Heuvel-Eibrink; V H J van der Velden; Anna M Aalbers; Brian Balgobind; Berna H Beverloo; Christian M Zwaan
High frequency of copy number alterations in myeloid leukaemia of Down syndrome.
British journal of haematology 2012;158(6):800-3.
2012: J J M van Dongen; María-Belén Vidriales; Julia Almeida; Vahid Asnafi; Sebastian Böttcher; Monika Brüggemann; M Cullen; Ruth de Tute; J Flores-Montero; Ondrej Hrusak; Tomas Kalina; Anton Langerak; Q Lécrevisse; L Lhermitte; Paulo Lucio; Elizabeth Macintyre; M Martin-Ayuso; Ester Mejstrikova; A Mendonça; Alberto Orfao; A Rawstron; L Sedek; T Szczepański; V H J van der Velden
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.
Leukemia 2012;26(9):1908-75.
2012: N C Venn; Esmé Waanders; V H J van der Velden; J J M van Dongen; M de Bie; V de Haas; J E Giles; M Haber; Roland P Kuiper; T Law; G M Marshall; Norris Md; Charles G Mullighan; R Sutton
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.
Leukemia 2012;26(6):1414-6.
2012: Nicole S D Larmonie; Jules P P Meijerink; V H J van der Velden; Jacques J M van Dongen; Berna Beverloo; Willem A Dik; Patricia G Hoogeveen; Anton Langerak
Correct interpretation of T-ALL oncogene expression relies on normal human thymocyte subsets as reference material.
British journal of haematology 2012;157(1):142-6.
2012: Theresia M Westers; August H Westra; Canan Alhan; Roelof Bekkema; André Bijkerk; Rik A Brooimans; Claudia Cali; V de Haas; Anja de Jong; Angelika M Dräger; Christa Homburg; P Ellen A Kuiper-Kramer; Marije Leenders; Ingrid Lommerse; Bijan Moshaver; Andre B Mulder; Frank W M B Preijers; Roger K Schindhelm; Jeroen G te Marvelde; Arjan A van de Loosdrecht; Joke K van der Molen-Sinke; Alita van der Sluijs; V H J van der Velden; Elisabeth R van Wering
Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.
Leukemia research 2012;36(4):422-30.
2012: Jeltje F de Vries; Monique L den Boer; J J M van Dongen; J S A Voerman; Christian M Zwaan; Maaike de Bie; V H J van der Velden
The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
Leukemia 2012;26(2):255-64.
2011: Tomasz Szczepanski; V H J van der Velden; Esmé Waanders; Roland P Kuiper; Pieter Van Vlierberghe; Bernd Gruhn; Cornelia Eckert; Renate Panzer-Grümayer; Giuseppe Basso; Hélène Cavé; Udo Zur Stadt; Dario Campana; André Schrauder; Rosemary Sutton; Elisabeth R van Wering; Jules P P Meijerink; Jacques J M van Dongen
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):1643-9.
2011: E M C Driessen; V H J van der Velden; C E Catsman-Berrevoets; M M van den Heuvel-Eibrink; A Beishuizen
Long-term survival after significant treatment reduction in a patient with CBF-AML.
Pediatric blood & cancer 2011;56(2):325-6.
2011: Esmé Waanders; V H J van der Velden; C E van der Schoot; Frank N Van Leeuwen; Simon van Reijmersdal; V de Haas; A J Veerman; Ad Geurts van Kessel; Peter M Hoogerbrugge; Roland P Kuiper; J J M van Dongen
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Leukemia 2011;25(2):254-8.
2010: E Dekking; V H J van der Velden; S Böttcher; Monika Brüggemann; E Sonneveld; A Koning-Goedheer; Nancy Boeckx; Paulo Lucio; L Sedek; T Szczepański; T Kalina; M Kovac; P Evans; Patricia G Hoogeveen; J Flores-Montero; Alberto Orfao; W Marieke Comans-Bitter; Frank Staal; J J M van Dongen
Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay.
Best practice & research. Clinical haematology 2010;23(3):333-45.
2010: V H J van der Velden; A van der Sluijs-Geling; B E S Gibson; Jeroen te Marvelde; Patricia G Hoogeveen; W C J Hop; K Wheatley; M B Bierings; G J Schuurhuis; Siebold S N de Graaf; Elisabeth R van Wering; J J M van Dongen
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
Leukemia 2010;24(9):1599-606.
2010: Jeltje F de Vries; Jeroen te Marvelde; Henk K Wind; Jacques J M van Dongen; V H J van der Velden
The potential use of basigin (CD147) as a prognostic marker in B-cell precursor acute lymphoblastic leukaemia.
British journal of haematology 2010;150(5):624-6.
2010: Arjan C Lankester; Marc Bierings; Elisabeth R van Wering; A J M Wijkhuijs; R A de Weger; Juul Wijnen; J M Vossen; B Versluys; R Maarten Egeler; M J D van Tol; H Putter; Tom Révész; J J M van Dongen; V H J van der Velden; Marco W Schilham
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
Leukemia 2010;24(8):1462-9.
2010: Roland P Kuiper; Esmé Waanders; V H J van der Velden; Simon van Reijmersdal; R Venkatachalam; B Scheijen; E Sonneveld; J J M van Dongen; A J P Veerman; Frank N Van Leeuwen; A Geurts van Kessel; Peter M Hoogerbrugge
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Leukemia 2010;24(7):1258-64.
2010: R Jung; U Jacobs; M Krumbholz; T Langer; T Keller; P De Lorenzo; M G Valsecchi; V H J van der Velden; A Moericke; M Stanulla; A Teigler-Schlegel; E R Panzer-Gruemayer; J J M van Dongen; M Schrappe; M L den Boer; R Pieters; W Rascher; M Metzler
Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment.
Leukemia 2010;24(4):903-7.
2010: Frank Staal; D de Ridder; T Szczepanski; T Schonewille; E C E van der Linden; Elisabeth R van Wering; V H J van der Velden; J J M van Dongen
Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype.
Leukemia 2010;24(3):491-9.
2009: A M Willasch; B Gruhn; T Coliva; M Kalinova; G Schneider; Hermann Kreyenberg; D Steinbach; G Weber; I H I M Hollink; Christian M Zwaan; A Biondi; V H J van der Velden; Dirk Reinhardt; G Cazzaniga; Peter Bader; Jan Trka
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Leukemia 2009;23(8):1472-9.
2009: H von Goessel; U Jacobs; S Semper; M Krumbholz; Thorsten Langer; T Keller; A Schrauder; V H J van der Velden; J J M van Dongen; Jochen Harbott; E R Panzer-Grümayer; M Schrappe; Wolfgang Rascher; Markus Metzler
Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia.
Leukemia research 2009;33(8):1082-8.
2009: Floor Weerkamp; E Dekking; Yuk Yin Ng; V H J van der Velden; Hobert Wai; S Böttcher; Monika Brüggemann; A J van der Sluijs; A Koning; Nancy Boeckx; N Van Poecke; Paulo Lucio; A Mendonça; L Sedek; T Szczepański; T Kalina; M Kovac; Patricia G Hoogeveen; J Flores-Montero; Alberto Orfao; Elizabeth Macintyre; L Lhermitte; R Chen; K A J Brouwer-De Cock; A van der Linden; A L Noordijk; W Marieke Comans-Bitter; Frank Staal; J J M van Dongen
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients.
Leukemia 2009;23(6):1106-17.
2009: V H J van der Velden; L Corral; Maria Grazia Valsecchi; M W J C Jansen; Paola de Lorenzo; Giovanni Cazzaniga; E Renate Panzer-Grümayer; Martin Schrappe; André Schrauder; Claus Meyer; Rolf Marschalek; L L Nigro; M Metzler; G Basso; G Mann; Monique L den Boer; A Biondi; Rob Pieters; J J M Van Dongen
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Leukemia 2009;23(6):1073-9.
2009: E Csinady; V H J van der Velden; R Joas; S Fischer; J F de Vries; Berna Beverloo; Margit König; Ulrike Pötschger; J J M van Dongen; Georg Mann; Oskar A Haas; E Renate Panzer-Grümayer
Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis.
Leukemia 2009;23(5):870-6.
2009: P L A van Daele; B S Beukenkamp; W M C Geertsma-Kleinekoort; P J M Valk; J A M van Laar; P Martin van Hagen; V H J van der Velden
Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis.
The Netherlands journal of medicine 2009;67(4):142-6.
2009: D Schotte; J C K Chau; G Sylvester; G Liu; C Chen; V H J van der Velden; M J C Broekhuis; T C J M Peters; Rob Pieters; Monique L den Boer
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.
Leukemia 2009;23(2):313-22.
2009: V H J van der Velden; Jacques J M van Dongen
MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
Methods in molecular biology (Clifton, N.J.) 2009;538():115-50.
2008: V H J van der Velden; J M Wijkhuijs; J J M van Dongen
Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring.
Leukemia 2008;22(3):641-4.
2007: J Saldanha; Monique Silvy; N Beaufils; R Arlinghaus; G Barbany; Susan Branford; Jean-Michel Cayuela; Giovanni Cazzaniga; M Gonzalez; David Grimwade; V Kairisto; K Miyamura; M Lawler; Thomas Lion; Elizabeth Macintyre; F-X Mahon; Martin C Muller; M Ostergaard; Heike Pfeifer; Giuseppe Saglio; Charles L Sawyers; Orietta Spinelli; V H J van der Velden; J Q Wang; K Zoi; V Patel; P Phillips; P Matejtschuk; Jean Gabert
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Leukemia 2007;21(7):1481-7.
2007: Roland B Walter; Theodore A Gooley; V H J van der Velden; Michael R Loken; Jacques J M van Dongen; David A Flowers; Irwin D Bernstein; Frederick R Appelbaum
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Blood 2007;109(10):4168-70.
2007: V H J van der Velden; E Renate Panzer-Grümayer; Giovanni Cazzaniga; T Flohr; R Sutton; André Schrauder; G Basso; Martin Schrappe; JM Wijkhuijs; M Konrad; C R Bartram; Guiseppe Masera; A Biondi; Jacques J M van Dongen
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
Leukemia 2007;21(4):706-13.
2007: G Mann; Giovanni Cazzaniga; V H J van der Velden; T Flohr; E Csinady; M Paganin; André Schrauder; Alexander Michael Dohnal; M Schrappe; A Biondi; Helmut Gadner; J J M van Dongen; E Renate Panzer-Grümayer
Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease?
Leukemia 2007;21(4):642-6.
2007: V H J van der Velden; Giovanni Cazzaniga; André Schrauder; J Hancock; Peter Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; Jean-Michel Cayuela; Jan Trka; Cornelia Eckert; Letizia Foroni; Udo zur Stadt; Kheira Beldjord; Thorsten Raff; C. Ellen van der Schoot; Jacques J M van Dongen
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
Leukemia 2007;21(4):604-11.
2007: M W J C Jansen; L Corral; V H J van der Velden; R Panzer-Grümayer; Martin Schrappe; André Schrauder; Rolf Marschalek; Claus Meyer; Monique L den Boer; W J C Hop; Maria Grazia Valsecchi; G Basso; A Biondi; Rob Pieters; Jacques J M van Dongen
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.
Leukemia 2007;21(4):633-41.
2007: V H J van der Velden; Berna Beverloo; Patricia G Hoogeveen; Ch M Zwaan
A novel BCR-ABL fusion transcript (e18a2) in a child with chronic myeloid leukemia.
Leukemia 2007;21(4):833-5.
2007: Yorick Sandberg; Ka Lung Wu; Freerk Heule; Renate R van den Bos; King H Lam; Anton Langerak; V H J van der Velden; Kirsten van Lom; Berna Beverloo
Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach.
Haematologica 2007;92(3):e34-6.
2006: V H J van der Velden; Kirsten van Lom; Patricia G Hoogeveen; Berna Beverloo; D A Breems
Unusual immunophenotypic shift in a patient with T-cell acute lymphoblastic leukemia.
Leukemia 2006;20(9):1626-9.
2006: Malgorzata Dawidowska; Katarzyna Derwich; Tomasz Szczepański; Justyna Jółkowska; V H J van der Velden; Jacek Wachowiak; Michal Witt
Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients--implications for RQ-PCR-based assessment of minimal residual disease.
Leukemia research 2006;30(9):1119-25.
2006: V H J van der Velden; Patricia G Hoogeveen; Rob Pieters; Jacques J M van Dongen
Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia.
British journal of haematology 2006;133(4):382-8.
2006: V H J van der Velden; Maaike de Bie; Elisabeth R van Wering; Jacques J M van Dongen
Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease.
Haematologica 2006;91(5):679-82.
2006: V H J van der Velden
Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation.
Haematologica 2006;91(3):291A.
2006: Volkher Scharnhorst; Jaap Wals; Berna Beverloo; Anton Langerak; V H J van der Velden
Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL.
Leukemia research 2006;30(2):245-6.
2006: Tomasz Szczepański; V H J van der Velden; Jacques J M van Dongen
Flow-cytometric immunophenotyping of normal and malignant lymphocytes.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(7):775-96.
2005: E Renate Panzer-Grümayer; Giovanni Cazzaniga; V H J van der Velden; Laura del Giudice; Martina Peham; Georg Mann; Cornelia Eckert; André Schrauder; Giuseppe Germano; Jochen Harbott; Giuseppe Basso; Andrea Biondi; Jacques J M van Dongen; Helmut Gadner; Oskar A Haas
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7720-7.
2005: Nancy Boeckx; J De Roover; V H J van der Velden; J Maertens; Anne Uyttebroeck; Peter Vandenberghe; Jacques J M van Dongen
Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR.
Leukemia 2005;19(11):1988-90.
2005: M W J C Jansen; V H J van der Velden; Jacques J M van Dongen
Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler.
Leukemia 2005;19(11):2016-8.
2005: AJ van der Sluijs-Gelling; V H J van der Velden; E T J M Roeffen; A J P Veerman; Elisabeth R van Wering
Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death.
Leukemia 2005;19(10):1845-7.
2005: AJ van der Sluijs-Gelling; V H J van der Velden; E T J M Roeffen; A J P Veerman; Elisabeth R van Wering
Reply to Gaipa et Al.
Leukemia 2005;19(10):1858.
2005: Nancy Boeckx; M W J C Jansen; C Haskovec; Peter Vandenberghe; V H J van der Velden; Jacques J M van Dongen
Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR.
Leukemia 2005;19(7):1292-5.
2004: V H J van der Velden; Monika Brüggemann; Patricia G Hoogeveen; Maaike de Bie; P G Hart; Thorsten Raff; Heike Pfeifer; Silke Lüschen; T Szczepański; Elisabeth R van Wering; Michael Kneba; Jacques J M van Dongen
TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.
Leukemia 2004;18(12):1971-80.
2004: Maria Malec; V H J van der Velden; Elisabet Björklund; JM Wijkhuijs; Stefan Söderhäll; Joanna Mazur; Magnus Björkholm; Anna Porwit-MacDonald
Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Leukemia 2004;18(10):1630-6.
2004: Nancy Boeckx; V H J van der Velden; Marc Boogaerts; Anne Hagemeijer; Peter Vandenberghe; Jacques J M van Dongen
An inv(16)(p13q22) positive acute myeloid leukaemia relapsing as acute precursor B-cell lymphoblastic leukaemia.
Haematologica 2004;89(8):ECR28.
2004: Ellen G van Lochem; V H J van der Velden; Henk Wind; Jeroen te Marvelde; N A C Westerdaal; Jacques J M van Dongen
Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts.
Cytometry. Part B, Clinical cytometry 2004;60(1):1-13.
2004: Tomasz Szczepanski; V H J van der Velden; Patricia G Hoogeveen; Maaike de Bie; D C H Jacobs; Elisabeth R van Wering; Jacques J M van Dongen
Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells.
Blood 2004;103(10):3798-804.
2004: V H J van der Velden; Nancy Boeckx; Inge Jedema; Jeroen te Marvelde; Patricia G Hoogeveen; Marc Boogaerts; Jacques J M van Dongen
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
Leukemia 2004;18(5):983-8.
2004: V H J van der Velden; Nancy Boeckx; Elisabeth R van Wering; Jacques J M van Dongen
Detection of minimal residual disease in acute leukemia.
Journal of biological regulators and homeostatic agents 2004;18(2):146-54.
2004: Monika Brüggemann; V H J van der Velden; Thorsten Raff; Jo Droese; Matthias Ritgen; Christiane Pott; A J M Wijkhuijs; Nicola Gökbuget; Dieter Hoelzer; Elisabeth R van Wering; Jacques J M van Dongen; Michael Kneba
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Leukemia 2004;18(4):709-19.
2004: V H J van der Velden; Nancy Boeckx; M Gonzalez; Maria Malec; G Barbany; Thomas Lion; Enrico Gottardi; N Pallisgaard; Emmanuel Beillard; W C J Hop; Patricia G Hoogeveen; Jean Gabert; Jacques J M van Dongen
Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program.
Leukemia 2004;18(4):884-6.
2004: Nicola E Annels; Annemieke J Willemze; V H J van der Velden; Claudia M J M Faaij; Elisabeth R van Wering; Daisy M D S Sie-Go; R Maarten Egeler; Maarten J D van Tol; Tom Révész
Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL.
Blood 2004;103(7):2806-8.
2004: Inge Jedema; Renée M Y Barge; V H J van der Velden; Bart A Nijmeijer; Jacques J M van Dongen; Rein Willemze; J H Frederik Falkenburg
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
Leukemia 2004;18(2):316-25.
2004: S Hübner; Giovanni Cazzaniga; T Flohr; V H J van der Velden; M Konrad; Ulrike Pötschger; G Basso; M Schrappe; J J M van Dongen; C R Bartram; A Biondi; E Renate Panzer-Grümayer
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias.
Leukemia 2004;18(1):84-91.
2003: Tomasz Szczepański; V H J van der Velden; Jacques J M van Dongen
Classification systems for acute and chronic leukaemias.
Best practice & research. Clinical haematology 2003;16(4):561-82.
2003: Jean Gabert; Emmanuel Beillard; V H J van der Velden; W Bi; David Grimwade; N Pallisgaard; G Barbany; Giovanni Cazzaniga; Jean-Michel Cayuela; H Cavé; Fabrizio Pane; J L E Aerts; D De Micheli; Xavier Thirion; Vincent Pradel; M González; Susanne Viehmann; Maria Malec; Giuseppe Saglio; Jacques J M van Dongen
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Leukemia 2003;17(12):2318-57.
2003: Emmanuel Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; Eric Delabesse; Elizabeth Macintyre; Enrico Gottardi; Giuseppe Saglio; Franz Watzinger; Thomas Lion; Jacques J M van Dongen; Peter Hokland; Jean Gabert
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia 2003;17(12):2474-86.
2003: T Szczepański; V H J van der Velden; Thorsten Raff; D C H Jacobs; Elisabeth R van Wering; Monika Brüggemann; Michael Kneba; Jacques J M van Dongen
Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL.
Leukemia 2003;17(11):2149-56.
2003: Ana Teresa Maia; V H J van der Velden; Christine J Harrison; T Szczepanski; M D Williams; M J Griffiths; J J M van Dongen; Mel F Greaves
Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins.
Leukemia 2003;17(11):2202-6.
2003: O Krejci; V H J van der Velden; Peter Bader; Hermann Kreyenberg; Nicholas J Goulden; J Hancock; M W Schilham; Arjan C Lankester; Tom Révész; Thomas Klingebiel; Jacques J M van Dongen
Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.
Bone marrow transplantation 2003;32(8):849-51.
2003: V H J van der Velden; Tomasz Szczepanski; JM Wijkhuijs; P G Hart; Patricia G Hoogeveen; W C J Hop; Elisabeth R van Wering; Jacques J M van Dongen
Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease.
Leukemia 2003;17(9):1834-44.
2003: Andreas Guggemos; Cornelia Eckert; Tomasz Szczepanski; Claudia Hanel; Tillmann Taube; V H J van der Velden; Hagen Graf Einsiedel; Günter Henze; Karl Seeger
Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
Haematologica 2003;88(7):737-46.
2003: Frank Staal; Mirjam van der Burg; Lodewyk F A Wessels; Barbara H Barendregt; Miranda Baert; Caroline M M van den Burg; Christophe Henri Van Huffel; Anton Langerak; V H J van der Velden; Marcel J T Reinders; Jacques J M van Dongen
DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.
Leukemia 2003;17(7):1324-32.
2003: Nicholas J Goulden; Peter Bader; V H J van der Velden; John Moppett; Marco Schilham; Hans O Masden; Ondrej Krejci; Hermann Kreyenberg; Arjan C Lankester; Tom Révész; Thomas Klingebiel; Jacques Van Dongen
Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.
British journal of haematology 2003;122(1):24-9.
2003: V H J van der Velden; A Hochhaus; Giovanni Cazzaniga; Tomasz Szczepanski; Jean Gabert; Jacques J M van Dongen
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
Leukemia 2003;17(6):1013-34.
2003: John Moppett; V H J van der Velden; A J M Wijkhuijs; J Hancock; Jacques J M van Dongen; Nicholas J Goulden
Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin.
Leukemia 2003;17(1):268-70.
2002: V de Haas; G J L Kaspers; L Oosten; Dorine Bresters; R Pieters; V H J van der Velden; Elisabeth R van Wering; H van den Berg; C Ellen van der Schoot
Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?
British journal of haematology 2002;118(4):1190-1.
2002: V H J van der Velden; D C H Jacobs; A J M Wijkhuijs; W Marieke Comans-Bitter; Marja J Willemse; Karel Hählen; Willem A Kamps; Elisabeth R van Wering; Jacques J M van Dongen
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
Leukemia 2002;16(8):1432-6.
2002: V H J van der Velden; JM Wijkhuijs; D C H Jacobs; Elisabeth R van Wering; Jacques J M van Dongen
T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.
Leukemia 2002;16(7):1372-80.
2002: V H J van der Velden; Marja J Willemse; C Ellen van der Schoot; Karel Hählen; Elisabeth R van Wering; Jacques J M van Dongen
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
Leukemia 2002;16(5):928-36.
2002: Tomasz Szczepański; Thomas Flohr; V H J van der Velden; Claus R Bartram; Jacques J M van Dongen
Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
Best practice & research. Clinical haematology 2002;15(1):37-57.
2002: Nancy Boeckx; Marja J Willemse; Tomasz Szczepanski; V H J van der Velden; Anton Langerak; P Vandekerckhove; Jacques J M van Dongen
Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
Leukemia 2002;16(3):368-75.
2001: V H J van der Velden; S A Joosten; Marja J Willemse; Elisabeth R van Wering; A W Lankester; Jacques J M van Dongen; P M Hoogerbrugge
Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia.
Leukemia 2001;15(9):1485-7.
2001: V H J van der Velden; Marja J Willemse; M F Mulder; T Szczepański; Anton Langerak; JM Wijkhuijs; Jacques J M van Dongen
Clearance of maternal leukaemic cells in a neonate.
British journal of haematology 2001;114(1):104-6.
2001: V H J van der Velden; MP Laan; Miranda Baert; Rene de Waal Malefyt; Herman J Neijens; Huub F J Savelkoul
Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2001;31(7):997-1006.
2001: V H J van der Velden; C Schoch; Anton Langerak; S Schnittger; Patricia G Hoogeveen; Jacques J M van Dongen
Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease.
British journal of haematology 2001;113(4):1082-3.
2001: V H J van der Velden; Jeroen te Marvelde; Patricia G Hoogeveen; Irwin D Bernstein; A B Houtsmuller; M S Berger; Jacques J M van Dongen
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
Blood 2001;97(10):3197-204.
2000: Arjen R Companjen; V H J van der Velden; A Vooys; R Debets; Robbert Benner; Errol P Prens
Human keratinocytes are major producers of IL-18: predominant expression of the unprocessed form.
European cytokine network 2000;11(3):383-90.
2000: V H J van der Velden; Brigitta A E Naber; PT van Hal; Shelley E Overbeek; Henk C Hoogsteden; Marjan A Versnel
Peptidases in the asthmatic airways.
Advances in experimental medicine and biology 2000;477():413-30.
1999: V H J van der Velden; Brigitta A E Naber; PT van Hal; Shelley E Overbeek; Henk C Hoogsteden; Marjan A Versnel
Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics--comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1999;29(6):813-23.
1999: V H J van der Velden; A R Hulsmann
Autonomic innervation of human airways: structure, function, and pathophysiology in asthma.
Neuroimmunomodulation 1999;6(3):145-59.
1999: V H J van der Velden; A R Hulsmann
Peptidases: structure, function and modulation of peptide-mediated effects in the human lung.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1999;29(4):445-56.
1998: V H J van der Velden; Brigitta A E Naber; Annet F Wierenga-Wolf; R Debets; Huub F J Savelkoul; Shelley E Overbeek; Henk C Hoogsteden; Marjan A Versnel
Interleukin 4 receptors on human bronchial epithelial cells. An in vivo and in vitro analysis of expression and function.
Cytokine 1998;10(10):803-13.
1998: V H J van der Velden; M M Verheggen; S Bernasconi; S Sozzani; Brigitta A E Naber; C A van der Linden-van Beurden; Henk C Hoogsteden; A Mantovani; Marjan A Versnel
Interleukin-1beta and interferon-gamma differentially regulate release of monocyte chemotactic protein-1 and interleukin-8 by human bronchial epithelial cells.
European cytokine network 1998;9(3):269-77.
1998: V H J van der Velden
Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma.
Mediators of inflammation 1998;7(4):229-37.
1998: V H J van der Velden; Annet F Wierenga-Wolf; P W Adriaansen-Soeting; Shelley E Overbeek; G M Möller; Henk C Hoogsteden; Marjan A Versnel
Expression of aminopeptidase N and dipeptidyl peptidase IV in the healthy and asthmatic bronchus.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1998;28(1):110-20.
1998: V H J van der Velden; Brigitta A E Naber; P van der Spoel; Henk C Hoogsteden; Marjan A Versnel
Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases.
Cytokine 1998;10(1):55-65.